Biotech Industry Fears Fallout From Supreme Court’s Myriad Ruling; PTO Offers Guidance
Executive Summary
Supreme Court unanimously holds that DNA isolated from the human body cannot be patented but cDNA, which is created in a laboratory, can; Patent and Trademark Office tells examiners to reject product claims drawn solely to naturally occurring nucleic acids or their fragments.
You may also be interested in...
Battle Begins Over Legislation To Expand What Inventions May Be Patented
BIO, PhRMA, AAM, former PTO Commissioners to testify at two-day Senate hearing on draft bill to revise Section 101 of Patent Act; ACLU coalition says legislation will allow patenting of human genes.
Biotech Patents May Be Easier To Get Under Revised PTO Guidance
Yielding to industry pressure, Patent and Trademark Office says both structural and functional changes to what exists in nature should to be considered in assessing patent claims.
Gene Patents: Supreme Court Could Be Swayed By Impact On Research
The outcome of ACLU’s suit challenging Myriad Genetics’ BRCA cancer genes is crucial for the biotech industry as it could prevent companies from getting patents on therapeutics that utilize DNA and other isolated molecules.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: